Strategic Analysis of the European Markets for Theranostics

Strategic Analysis of the European Markets for Theranostics


May 26, 2009
53 Pages - SKU: MC2445590
License type:
Electronic Access - Single User      US $6,500.00
Electronic Access - Global Site License      US $8,000.00
Hard Copy Mail Delivery      US $7,000.00
Countries covered: Europe



This Frost & Sullivan research service titled Strategic Analysis of the European Markets for Theranostics provides a strategic analysis of the theranostics market in Europe. This research service focuses on the current scenario in the market, its dynamics and the regulatory scenario. It also includes competitive analysis and strategic recommendations for current industry challenges. In this research, Frost & Sullivan's expert analysts thoroughly examine the key applications of theranostics in the following disease areas: cancer, cardiovascular diseases and neuro disorders.

Market Overview

Theranostics Ushers in Personalised Medicine in Europe - A Milestone in the Drug Therapy Process

Theranostics, an emerging field in clinical diagnostics, focuses on developing specific analysis to predict the most suitable drug for a patient as well as assesses the efficacy of the drug. It uses molecular assays to determine the optimum dose of drugs for a patient, ushering in personalised medicine. Although significant awareness has been created about personalised medicine, its full potential is yet to be tapped. Factors such as cost and regulatory timelines are the key hurdles that need to be addressed at the moment. "The emergence of personalised medicine with the help of theranostics is a milestone in the drug therapy process," says the analyst of this research. "Its targeted approach enables the prescription of only those drugs that are linked to a specific biomarker assay, thereby benefiting the physicians, patients, insurance, and regulatory agencies." The availability of advanced technology to support research projects has resulted in novel therapeutics. As more biomarkers are discovered and their importance known, the need for specific theranostic assays is likely to increase.

However, the high cost associated with genetic testing for the identification of biomarkers poses a challenge to the success of theranostics. The uncertainty associated with the clinical utility of biomarkers discovered will negatively impact the return-on-investment (ROI). "Theranostics is a well understood science, yet pharmaceutical companies have been late adopters," says the analyst. "It is rare to see large pharma and diagnostic companies branding themselves as theranostic companies."

Improved cooperation between drug and diagnostic companies will enhance the success of theranostics. The commercialisation of theranostics will be possible by effective communication with the physicians to understand its penetration in the market. "Companies focusing on theranostics with already licensed drugs can play a key role in reaching out to larger pharmaceutical companies," concludes the analyst. "Pharmaceutical companies should be aware of the importance of linking diagnostics to its drug development process."



More Molecular Assays reports by Frost & Sullivan

U.S. qPCR Reagents Market by Frost & Sullivan
U.S. qPCR Reagents Market This research service evaluates the U.S. qPCR reagents market from 2010 to 2017. The mature qPCR reagents market remains dynamic due ...
U.S. Companion Diagnostics Markets by Frost & Sullivan
This analysis provides a detailed view of the U.S. companion diagnostics market. This segments present an executive summary highlighting key analysis and findings pertaining to ...
Rapid Advances in HIV/AIDS Clinical Diagnostics (Technical Insights) by Frost & Sullivan
This research service provides the latest trends in HIV molecular diagnostics and discusses the prospects of future developments in this segment. ...
See all reports like this >>

More Europe Molecular Assays reports

Snapshots Denmark Fragrances 2009 by Mintel - Snapshots
Snapdata's Snapshots Denmark Fragrances 2009 provides 2008 year-end market size data, with 2009 estimates, 5 years of historical data and five-year forecasts. The Snapshots report ...
Europe In Vitro Diagnotics Investment Opportunities, Analysis and Forecasts to 2015 by Global Markets Direct
Europe In Vitro Diagnotics Investment Opportunities, Analysis and Forecasts to 2015SummaryThis report is an essential source for in-depth information and data relating to Europe In ...
See all reports like this >>

More Europe reports

Tobacco Retailing in Sweden: Market Snapshot to 2017 by Canadean Ltd
Tobacco Retailing in Sweden: Market Snapshot to 2017SynopsisCanadean’s, Tobacco Retailing in Sweden: Market Snapshot to 2017 contains detailed historic and forecast retail sales values of ...
Painters & Decorators - Scotland (UK) - Industry Report by Plimsoll Publishing Ltd.
Plimsoll Publishing’s UK Painters & Decorators - Scotland Analysis provides a detailed overview of the UK Painters & Decorators - Scotland market and delivers a ...
Plastic Headgear Markets in Western Europe to 2017 - Market Size, Trends, and Forecasts by Global Research & Data Services
Plastic Headgear Markets in Western Europe to 2017 - Market Size, Trends, and ForecastsThe industry report package Plastic Headgear Markets in Western Europe to 2017 ...
European SMB Market Watch Update: January–March 2013 by IDC
This IDC Update presents coverage of the European SMB sector in the first quarter of 2013, with a focus on new products and services, initiatives, ...
See all reports like this >>